Yes, it absolutely matters as it defines the tech itself and not just Eli-200. This is why I think the stock tanked during Pfizer's Adcom vote yesterday. We have a very similar pharmacologic tech to theirs. Theirs is struggling and can be easily extrapolated that Elite's tech will have the same issues. PFE claimed 30 solvents were used during trials. Elite used half this amount. What is to say Elite even tried using the same solvent that is causing extraction concerns? We simply don't know until the extraction data is made public.
On another note both Teva & PFE had their adcom's delayed. I hope we still hear back from FDA timely.
The purpose of this post is to show that not everything is puppy dogs & rainbows as some on this board would like you to believe. We are not out of the woods yet...
News 
Market Data 
Discover 
